-

09:59:10 PM

NRXP Stock News

NRXP - NRX Pharmaceuticals Inc

10/14/21 6:48 AM

Nasdaq : NRXP

covid-19

Journal of Infectious Diseases and Treatment Publishes Positive Trial Data of Aviptadil in High Comorbidity Patients Suffering from Critical COVID-19 with Respiratory Failure

NRx Pharmaceuticals (Nasdaq: NRXP), today announced the publication of peer-reviewed results from a prospective, open-label, administratively controlled trial of aviptadil for the treatment of respiratory failure in patients with Critical COVID-19. The

RHEA-AI

neutral

10/12/21 6:48 AM

Nasdaq : NRXP

NRx Pharmaceuticals Announces Progress on Worldwide Commercial Scale Development of ZYESAMI™ (aviptadil)

NRx Pharmaceuticals (Nasdaq: NRXP ), today announced that a revised Investigational New Drug module on the manufacturing of ZYESAMI™ (aviptadil) was submitted to the US Food and Drug Administration (FDA), containing documentation that confirmed Nephron

RHEA-AI

very positive

09/29/21 6:48 AM

Nasdaq : NRXP

covid-19

NRx Pharmaceuticals Announces Second Favorable Safety Report for ZYESAMI™ (aviptadil) in NIH Sponsored ACTIV-3b Critical Care Study in Patients with Life-Threatening COVID-19

NRx Pharmaceuticals (NRx) (NASDAQ: NRXP), a clinical stage, biopharmaceutical company today provided a safety update on ZYESAMI™ (aviptadil) which is being tested in the ACTIV-3b Critical Care Phase 3 study sponsored by the National Institutes of Health.

RHEA-AI

very negative

09/27/21 7:04 AM

Nasdaq : NRXP

covid-19

NRx Pharmaceuticals Announces Improved Survival at One Year in Highly Comorbid COVID-19 Patients Treated with ZYESAMI (aviptadil)

NRx Pharmaceuticals (Nasdaq: NRXP), a clinical stage, biopharmaceutical company, today announced top line data demonstrating improved outcomes at one year in highly comorbid patients with COVID-19 who were treated with ZYESAMI™."These latest data are

RHEA-AI

neutral

09/13/21 4:15 PM

NYSE, Nasdaq : IQV, NRXP

covid-19

IQVIA and NRx Pharmaceuticals Collaborate on Potential Medical Support for Novel COVID-19 Treatment

IQVIA™, a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced a transformative collaboration with NRx Pharmaceuticals. New medicines with new mechanisms of action are urgently needed, "said Robert Besthof, chief commercial officer and head of Operations of NRx.

RHEA-AI

positive

09/08/21 7:48 AM

Nasdaq : NRXP

conferences

NRx Pharmaceuticals to Participate in H.C. Wainwright 23rd Annual Global Investment Conference

NRx Pharmaceuticals (NRx) (Nasdaq: NRXP) today announced that NRx's management team will present and host one-on-one investor meetings at the upcoming H.C. Wainwright Global Investment Conference September 13-15, 2021.Conference:H.C. Wainwright 23rd

RHEA-AI

neutral

08/26/21 6:48 AM

Nasdaq : NRXP

NRx Pharmaceuticals to Work with Cardinal Health to Ensure Efficient Distribution of Potential Therapies

NRx Pharmaceuticals (NRx) (Nasdaq: NRXP) announced today it has signed an agreement with Cardinal Health to provide third party logistics and distribution of ZYESAMI™ upon the potential Emergency Use Authorization (EUA) approval by the US Food and Drug

RHEA-AI

positive

08/24/21 6:48 AM

Nasdaq : NRXP

NRx Pharmaceuticals Announces Closing of $30 Million Private Placement

NRx Pharmaceuticals (Nasdaq: NRXP), today announced that it has completed its previously announced private placement for the purchase of 2,727,273 shares of common stock. The Company issued to the investors in the private placement unregistered preferred

RHEA-AI

neutral

08/23/21 9:33 AM

Nasdaq : NRXP

covid-19

Participants in High Dose BriLife™ Investigational Vaccine Trial for COVID-19 Advised Booster Not Necessary

NRx Pharmaceuticals (NRx) (Nasdaq: NRXP), a clinical stage, biopharmaceutical company noted today reports 1 in the Israeli media that participants in the BriLife vaccine trial who received the highest dose vaccine were notified by local health authorities

RHEA-AI

neutral

08/19/21 9:18 AM

Nasdaq : NRXP

NRx Pharmaceuticals Announces $30 Million Private Placement

NRx Pharmaceuticals (NRx) (Nasdaq: NRXP) (or the "Company"), a Delaware corporation, today announced that it has entered into definitive agreements with investors to purchase 2,727,273 shares of common stock in a private placement. The Company will also

RHEA-AI

neutral

NRXP Data:

IndustryMedicinal and Botanical Manufacturing
Websitewww.bigrockpartners.com/spac/spac_aboutus.html
Security nameNRX Pharmaceuticals Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees2
Address2645 N Federal Hwy Ste 230
StateFlorida
CityDelray Beach
Zip33483-6111
CountryUS
Phone13107342300

NRXP Description:

Big Rock Partners is a blank check company formed for the purpose of entering into a merger, stock exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. Big Rock Partners' management team includes Richard Ackerman, Chairman, President, and Chief Executive Officer, and Bennett Kim, Chief Financial Officer, Chief Investment Officer, Corporate Secretary and Director.